Activist Investor Laser Shines On Latest Pharma Target
This article was originally published in Scrip
We don't wish to speculate on the personal reasons that prompted Bavarian Nordic A/S's executive vice president and chief development officer Dr Jim Breitmeyer to resign on Aug. 5, two days after famed short seller Sahm Adrangi's hedge fund Kerrisdale Capital turned its laser on the Danish firm. Suffice to say, his resignation releases him from what promises to be an unpleasant and drawn-out short-selling campaign.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.